scPharmaceuticals to Present at the Jefferies Healthcare Conference
May 31, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023 16:01 ET
|
scPharmaceuticals, Inc.
Announced launch and commercial availability of FUROSCIX® on February 20th Generated net FUROSCIX revenue of $2.1 million Ended Q1 2023 with cash, cash equivalents and short-term investments...
scPharmaceuticals to Announce First Quarter 2023 Financial Results on Wednesday, May 10, 2023
May 02, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update
March 22, 2023 16:05 ET
|
scPharmaceuticals, Inc.
Announced launch and commercial availability of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic...
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22
March 15, 2023 08:00 ET
|
scPharmaceuticals, Inc.
Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on...
scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care Conference
February 23, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX® (furosemide injection)
February 21, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing...
scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
January 31, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update
January 30, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...